COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT01363011




Registration number
NCT01363011
Ethics application status
Date submitted
11/05/2011
Date registered
1/06/2011
Date last updated
2/05/2016

Titles & IDs
Public title
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Scientific title
A Phase 3 Open-label Safety Study of Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Secondary ID [1] 0 0
GS-US-236-0118
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Acquired Immunodeficiency Syndrome 0 0
HIV Infections 0 0
Condition category
Condition code
Infection 0 0 0 0
Acquired immune deficiency syndrome (AIDS / HIV)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - E/C/F/TDF
Treatment: Drugs - COBI
Treatment: Drugs - ATV
Treatment: Drugs - DRV
Treatment: Drugs - NRTI

Experimental: E/C/F/TDF (Cohort 1) - Participants who have not received prior antiretroviral (ARV) treatment and who are virologically unsuppressed at baseline will initiate treatment with elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) single-tablet regimen (STR) for up to 96 weeks.
Following Week 96, participants continued their treatment until all participants discontinued from the study or commercial approval of E/C/F/TDF was received in the applicable country.

Experimental: COBI+PI+2 NRTI (Cohort 2) - Participants who have received prior ARV treatment and who are virologically suppressed at baseline will continue their treatment regimen, switching the regimen's pharmacoenhancer component from ritonavir to cobicistat (COBI), and continuing their existing protease inhibitor (PI; either atazanavir (ATV) or darunavir (DRV)) plus 2 nucleoside reverse transcriptase inhibitor (NRTI) regimen for up to 96 weeks.
Following Week 96, participants continued their treatment until all participants discontinued from the study or commercial approval of cobicistat was received in the applicable country.


Treatment: Drugs: E/C/F/TDF
E/C/F/TDF (150/150/200/300 mg) STR administered orally once daily

Treatment: Drugs: COBI
COBI 150 mg tablet administered with food orally once daily

Treatment: Drugs: ATV
ATV 300 mg tablet administered orally once daily

Treatment: Drugs: DRV
DRV 800 mg tablet administered orally once daily

Treatment: Drugs: NRTI
Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC, 3TC, tenofovir disoproxil fumarate (TDF), or FTC/TDF, administered according to prescribing information.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) Using the Cockcroft-Gault (CG) Equation at Week 24 (Cohort 1) - Change from baseline in eGFR-CG equation at Week 24 was analyzed in Cohort 1 (treatment-naive).
Timepoint [1] 0 0
Baseline; Week 24
Primary outcome [2] 0 0
Change From Baseline in eGFR-CG at Week 24 (Cohort 2) - Change from baseline in eGFR-CG equation at Week 24 was analyzed in Cohort 2 (treatment-experienced).
Timepoint [2] 0 0
Baseline; Week 24
Primary outcome [3] 0 0
Change From Baseline in eGFR Using the Modification of Diet in Renal (MDRD) Equation at Week 24 (Cohort 1) - Change from baseline in eGFR-MDRD equation at Week 24 was analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area.
Timepoint [3] 0 0
Baseline; Week 24
Primary outcome [4] 0 0
Change From Baseline in eGFR-MDRD at Week 24 (Cohort 2) - Change from baseline in eGFR-MDRD equation at Week 24 was analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area.
Timepoint [4] 0 0
Baseline; Week 24
Primary outcome [5] 0 0
Change From Baseline in eGFR Using the Chronic Kidney Disease, Epidemiology Collaboration (CKD-EPI) Formula Based on Cystatin C Equation at Week 24 (Cohort 1) - Change from baseline in eGFR-CKD-EPI based on cystatin C equation (not adjusted for age, sex, and race) at Week 24 was analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area.
Timepoint [5] 0 0
Baseline; Week 24
Primary outcome [6] 0 0
Change From Baseline in eGFR-CKD-EPI Formula Based on Cystatin C Equation at Week 24 (Cohort 2) - Change from baseline in eGFR-CKD-EPI based on cystatin C equation (not adjusted for age, sex, and race) at Week 24 was analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area.
Timepoint [6] 0 0
Baseline; Week 24
Primary outcome [7] 0 0
Change From Baseline in eGFR-CKD-EPI Based on Cystatin C Equation, Adjusted at Week 24 (Cohort 1) - Change from baseline in eGFR-CKD-EPI based on cystatin C equation (adjusted for age, sex, and race) at Week 24 was analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area.
Timepoint [7] 0 0
Baseline; Week 24
Primary outcome [8] 0 0
Change From Baseline in eGFR-CKD-EPI Based on Cystatin C Equation, Adjusted at Week 24 (Cohort 2) - Change from baseline in eGFR-CKD-EPI based on cystatin C equation (adjusted for age, sex, and race) at Week 24 was analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area.
Timepoint [8] 0 0
Baseline; Week 24
Primary outcome [9] 0 0
Change From Baseline in Actual Glomerular Filtration Rate (aGFR) at Weeks 2, 4, and 24 (Cohort 1) - Change from baseline in aGFR at Weeks 2, 4, and 24 was analyzed in Cohort 1 (treatment-naive). aGFR was calculated using iohexol plasma clearance.
Timepoint [9] 0 0
Baseline; Weeks 2, 4, and 24
Primary outcome [10] 0 0
Change From Baseline in aGFR at Weeks 2, 4, and 24 (Cohort 2) - Change from baseline in aGFR at Weeks 2, 4, and 24 was analyzed in Cohort 2 (treatment-experienced). aGFR was calculated using iohexol plasma clearance.
Timepoint [10] 0 0
Baseline; Weeks 2, 4, and 24
Primary outcome [11] 0 0
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 (Cohort 1) - The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed in Cohort 1 (treatment-naive) using the FDA snapshot analysis algorithm.
Timepoint [11] 0 0
Week 24
Primary outcome [12] 0 0
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 (Cohort 2) - The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed in Cohort 2 (treatment-experienced) using the FDA snapshot analysis algorithm.
Timepoint [12] 0 0
Week 24
Secondary outcome [1] 0 0
Change From Baseline in eGFR-CG at Weeks 48 and 96 (Cohort 1) - Change from baseline in eGFR-CG at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive). This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters.
Timepoint [1] 0 0
Baseline; Weeks 48 and 96
Secondary outcome [2] 0 0
Change From Baseline in eGFR-CG at Weeks 48 and 96 (Cohort 2) - Change from baseline in eGFR-CG at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced). This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters.
Timepoint [2] 0 0
Baseline; Week 48
Secondary outcome [3] 0 0
Change From Baseline in eGFR-MDRD at Weeks 48 and 96 (Cohort 1) - Change from baseline in eGFR-MDRD at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters.
Timepoint [3] 0 0
Baseline; Weeks 48 and 96
Secondary outcome [4] 0 0
Change From Baseline in eGFR-MDRD at Weeks 48 and 96 (Cohort 2) - Change from baseline in eGFR-MDRD at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters.
Timepoint [4] 0 0
Baseline; Weeks 48 and 96
Secondary outcome [5] 0 0
Change From Baseline in eGFR-CKD-EPI Based on Cystatin C Equation at Weeks 48 and 96 (Cohort 1) - Change from baseline in eGFR-CKD-EPI based on cystatin C equation (not adjusted for age, sex, and race) at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters.
Timepoint [5] 0 0
Baseline; Weeks 48 and 96
Secondary outcome [6] 0 0
Change From Baseline in eGFR-CKD-EPI Based on Cystatin C Equation at Weeks 48 and 96 (Cohort 2) - Change from baseline in eGFR-CKD-EPI based on cystatin C equation (not adjusted for age, sex, and race) at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters.
Timepoint [6] 0 0
Baseline; Weeks 48 and 96
Secondary outcome [7] 0 0
Change From Baseline in eGFR-CKD-EPI Based on Cystatin C Equation (Adjusted) at Weeks 48 and 96 (Cohort 1) - Change from baseline in eGFR-CKD-EPI based on cystatin C equation (adjusted for age, sex, and race) at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters.
Timepoint [7] 0 0
Baseline; Weeks 48 and 96
Secondary outcome [8] 0 0
Change From Baseline in eGFR-CKD-EPI Based on Cystatin C Equation (Adjusted) at Weeks 48 and 96 (Cohort 2) - Change from baseline in eGFR-CKD-EPI based on cystatin C equation (adjusted for age, sex, and race) at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters.
Timepoint [8] 0 0
Baseline; Weeks 48 and 96
Secondary outcome [9] 0 0
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Weeks 48 and 96 (Cohort 1) - The percentage of participants with HIV-1 RNA < 50 copies/mL at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive) using the FDA snapshot analysis algorithm.
Timepoint [9] 0 0
Weeks 48 and 96
Secondary outcome [10] 0 0
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Weeks 48 and 96 (Cohort 2) - The percentage of participants with HIV-1 RNA < 50 copies/mL at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced) using the FDA snapshot analysis algorithm.
Timepoint [10] 0 0
Weeks 48 and 96
Secondary outcome [11] 0 0
Percentage of Participants Who Experienced Adverse Events (Cohort 1) - Adverse events (AEs) occurring from baseline up to 30 days following the last dose of study drug were summarized for Cohort 1 (treatment-naive). A participant was counted once if they had a qualifying event.
Timepoint [11] 0 0
Up to 147 weeks plus 30 days
Secondary outcome [12] 0 0
Percentage of Participants Who Experienced Adverse Events (Cohort 2) - Adverse events (AEs) occurring from baseline up to 30 days following the last dose of study drug were summarized for Cohort 2 (treatment-experienced). A participant was counted once if they had a qualifying event.
Timepoint [12] 0 0
Up to 166 weeks plus 30 days
Secondary outcome [13] 0 0
Percentage of Participants Who Experienced Graded Laboratory Abnormalities (Cohort 1) - Laboratory abnormalities were summarized for Cohort 1 (treatment-naive) and were defined as values that increased at least one toxicity grade from baseline at any time postbaseline up to and including the date of last dose of study drug plus 30 days. A participant was counted once if they had a qualifying event.
Timepoint [13] 0 0
Up to 147 weeks plus 30 days
Secondary outcome [14] 0 0
Percentage of Participants Who Experienced Graded Laboratory Abnormalities (Cohort 2) - Laboratory abnormalities were summarized for Cohort 2 (treatment-experienced) and were defined as values that increased at least one toxicity grade from baseline at any time postbaseline up to and including the date of last dose of study drug plus 30 days. A participant was counted once if they had a qualifying event.
Timepoint [14] 0 0
Up to 166 weeks plus 30 days
Secondary outcome [15] 0 0
Plasma Pharmacokinetics of COBI: AUCtau (Cohort 1) - AUCtau was analyzed for Cohort 1 (treatment-naive) and was defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval).
Timepoint [15] 0 0
Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
Secondary outcome [16] 0 0
Plasma Pharmacokinetics of COBI: AUCtau (Cohort 2) - AUCtau was analyzed for Cohort 2 (treatment-experienced) and was defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval).
Timepoint [16] 0 0
Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
Secondary outcome [17] 0 0
Plasma Pharmacokinetics of COBI: Cmax (Cohort 1) - Cmax was analyzed for Cohort 1 (treatment-naive) and was defined as the maximum observed concentration of drug in plasma.
Timepoint [17] 0 0
Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
Secondary outcome [18] 0 0
Plasma Pharmacokinetics of COBI: Cmax (Cohort 2) - Cmax was analyzed for Cohort 2 (treatment-experienced) and was defined as the maximum observed concentration of drug in plasma.
Timepoint [18] 0 0
Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
Secondary outcome [19] 0 0
Plasma Pharmacokinetics of COBI: Ctau (Cohort 1) - Ctau was analyzed for Cohort 1 (treatment-naive) and was defined as the observed drug concentration at the end of the dosing interval.
Timepoint [19] 0 0
Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
Secondary outcome [20] 0 0
Plasma Pharmacokinetics of COBI: Ctau (Cohort 2) - Ctau was analyzed for Cohort 2 (treatment-experienced) and was defined as the observed drug concentration at the end of the dosing interval.
Timepoint [20] 0 0
Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
Secondary outcome [21] 0 0
Plasma Pharmacokinetics of COBI: Tmax (Cohort 1) - Tmax was analyzed for Cohort 1 (treatment-naive) and was defined as the time of Cmax.
Timepoint [21] 0 0
Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
Secondary outcome [22] 0 0
Plasma Pharmacokinetics of COBI: Tmax (Cohort 2) - Tmax was analyzed for Cohort 2 (treatment-experienced) and was defined as the time of Cmax.
Timepoint [22] 0 0
Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
Secondary outcome [23] 0 0
Plasma Pharmacokinetics of COBI: t1/2 (Cohort 1) - t1/2 was analyzed for Cohort 1 (treatment-naive) and was defined as the estimate of the terminal elimination half-life of the drug.
Timepoint [23] 0 0
Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
Secondary outcome [24] 0 0
Plasma Pharmacokinetics of COBI: t1/2 (Cohort 2) - t1/2 was analyzed for Cohort 2 (treatment-experienced) and was defined as the estimate of the terminal elimination half-life of the drug.
Timepoint [24] 0 0
Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.

Eligibility
Key inclusion criteria
Cohort 1 (treatment-naive)

- Plasma HIV-1 RNA levels = 1,000 copies/mL at screening

- Screening genotype report must show sensitivity to FTC and TDF

- No prior use of any approved or investigational antiretroviral drug for any length of
time

Cohort 2 (treatment-experienced, pharmacoenhancer switch)

- Subjects must be receiving ATV 300 mg/ritonavir (RTV) 100 mg plus 2 NRTIs OR DRV 800
mg/RTV 100 mg plus 2 NRTIs for at least 6 months prior to screening

- Plasma HIV-1 RNA concentrations at undetectable levels in the 6 months preceding the
screening visit and have HIV-1 RNA < 50 copies/mL at screening

- Subjects experiencing intolerance to RTV (as determined by the investigator)

Both groups

- The ability to understand and sign a written informed consent form

- Normal ECG

- Mild to moderate renal function

- Stable renal function

- Hepatic transaminases (AST and ALT) = 5 x the upper limit of the normal range (ULN)

- Total bilirubin = 1.5 mg/dL, or normal direct bilirubin (subjects with documented
Gilbert's Syndrome or hyperbilirubinemia due to atazanavir therapy may have total
bilirubin up to 5 x ULN)

- Adequate hematologic function

- Serum amylase = 5 x ULN

- Males and females of childbearing potential must agree to utilize highly effective
contraception methods from screening throughout the duration of study treatment and
for 30 days following the last dose of study drug

- Age = 18 years
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- New AIDS-defining condition diagnosed within the 30 days prior to screening

- Receiving drug treatment for hepatitis C, or anticipated to receive treatment for
hepatitis C

- Subjects experiencing decompensated cirrhosis

- Females who are breastfeeding

- Positive serum pregnancy test (female of childbearing potential)

- Implanted defibrillator or pacemaker

- Current alcohol or substance use judged by the investigator to potentially interfere
with subject study compliance

- History of malignancy within the past 5 years or ongoing malignancy other than
cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, noninvasive cutaneous
squamous carcinoma

- Active, serious infections (other than HIV-1 infection) requiring parenteral
antibiotic or antifungal therapy within 30 days prior to baseline

- Receiving ongoing therapy with any of medications contraindicated for use with
elvitegravir (EVG), COBI, FTC, TDF, ATV, DRV; or subjects with any known allergies to
the excipients of E/C/F/TDF STR, COBI tablets, ATV capsules or DRV tablets or
contraindicated for the 2 NRTIs as part of the PI/co regimen

- Participation in any other clinical trial without prior approval

- Any other clinical condition or prior therapy that would make the subject unsuitable
for the study or unable to comply with the dosing requirements

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Taylor Square Private Clinic - Darlinghurst
Recruitment hospital [2] 0 0
Infectious Diseases Unit - The Alfred Hospital - Melbourne
Recruitment hospital [3] 0 0
Holdsworth House Medical Practice - Sydney
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
3004 - Melbourne
Recruitment postcode(s) [3] 0 0
2010 - Sydney
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
District of Columbia
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
New Jersey
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
North Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
Austria
State/province [16] 0 0
Graz
Country [17] 0 0
Austria
State/province [17] 0 0
Wien
Country [18] 0 0
Canada
State/province [18] 0 0
Ontario
Country [19] 0 0
Canada
State/province [19] 0 0
Montreal
Country [20] 0 0
Dominican Republic
State/province [20] 0 0
Santo Domingo
Country [21] 0 0
Germany
State/province [21] 0 0
Düsseldorf
Country [22] 0 0
Mexico
State/province [22] 0 0
Guadalajara
Country [23] 0 0
Puerto Rico
State/province [23] 0 0
San Juan
Country [24] 0 0
United Kingdom
State/province [24] 0 0
Brighton
Country [25] 0 0
United Kingdom
State/province [25] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Gilead Sciences
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is to characterize the effect of cobicistat-based regimens on parameters of renal
function in participants with HIV infection and who have mild to moderate renal impairment,
and to assess the safety and tolerability of the regimens in order to generate appropriate
dosing recommendations.
Trial website
https://clinicaltrials.gov/show/NCT01363011
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Javier Szwarcberg, MD
Address 0 0
Gilead Sciences
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications